Check out the latest news from Tavanta

October 29, 2019

DRGT Announces First Subject Dosed in a Phase I Clinical Trial of DRGT-45, a Novel Formulation of Abiraterone Acetate for Prostate Cancer

October 21, 2019

Druggability Technologies Holdings, Ltd (DRGT) Announces Appointment of a New Chief Executive Officer and New President of DRGT Research

September 18, 2019

DRGT Announces the U.S. FDA IND Application Approval and First Dosing of a Clinical Trial to Evaluate the Bioavailability and Food Effect of Immediate-Release Formulation of Tadalafil (DRGT-99)

July 15, 2019

DRGT Announces Hungarian Regulatory Authority Approval and Subsequent Initiation of a Phase 2 Trial of DRGT-119 in Patients With Chronic Anal Fissure

June 10, 2019

DRGT Completes a Pivotal Phase I Trial; Results Confirm 6X Faster Attainment Of Maximum Plasma Levels For Pain Management Compared To Currently Available COX-2 Inhibitor

February 05, 2019

DRGT USA Announces Appointment of Dr. Elizabeth Manning Duus, as Executive Director of Clinical Development

December 06, 2018

Druggability Technologies USA Announces Appointment of John E. Friend II, M.D. as Chief Medical Officer

May 02, 2018

Best in Class Erectile Dysfunction Drug – DRGT announces dose escalation study results of its Super-Tadalafil DRGT-99